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ABSTRACT: A prospective, large library virtual screen against an activated
β2-adrenergic receptor (β2AR) structure returned potent agonists to the
exclusion of inverse-agonists, providing the first complement to the previous
virtual screening campaigns against inverse-agonist-bound G protein
coupled receptor (GPCR) structures, which predicted only inverse-agonists.
In addition, two hits recapitulated the signaling profile of the co-crystal
ligand with respect to the G protein and arrestin mediated signaling. This
functional fidelity has important implications in drug design, as the ability to
predict ligands with predefined signaling properties is highly desirable. However, the agonist-bound state provides an uncertain
template for modeling the activated conformation of other GPCRs, as a dopamine D2 receptor (DRD2) activated model
templated on the activated β2AR structure returned few hits of only marginal potency.
The recent abundance of crystal structures of G proteincoupled receptors (GPCRs) has inspired a surge of
structure-based discovery campaigns against these targets. In
the past three years, prospective docking screens of large
chemical libraries have been prosecuted against the β2-
adrenergic receptor (β2AR), the adenosine A2A receptor, the
histamine H1 receptor, the dopamine D3 receptor, and the
chemokine CXC-4 receptor.1−6 Despite the use of multiple
docking programs by several independent groups, three
unifying features have emerged: (1) hit rates are unusually
high, ranging from 17% to 70% (compounds active/tested); (2)
hits are unusually potent; and (3) the activity of the hits has
recapitulated the activity of the co-crystallized inverse-agonist;
all GPCR crystal structures used for virtual screening were
solved in the inactive state, and all hits predicted by virtual
screening were subsequently confirmed to be inverse-agonists.
The recently determined structure of the β2AR in an
activated state revealed surprisingly subtle changes in the
orthosteric binding site,7,8 supporting the idea that agonist
binding and activation requires only modest conformational
change in that region.9−13 The slight conformational change is
subsequently translated to much larger changes at the
intracellular G protein interface, nearly 40 Å away. Given the
small differences between the active and inactive binding site
conformation, the functional fidelity of docking hits to the state
of the receptor is surprising.
Two explanations for the high hit rates and affinities of
GPCR ligands predicted by docking are possible: GPCR
binding sites may be unusually well suited to small molecule
binding, or docking libraries may be biased toward analogues of
signaling molecules.14 By extension, it may be that (1) the
inverse-agonist-bound GPCR states are genuinely selective for
inverse-agonists; (2) the libraries are biased toward inverse-
agonists; or (3) a combination of the two. If the docking results
reflect structural information encoded in the binding site
conformation, one might expect agonist hits to dominate
docking campaigns against the active structure. Conversely, if
library bias dominates, one might expect the screen to return
molecules that resemble the docking library used. In the second
case, a ligand-based screen would return molecules that
resemble the structure-based docking hits.
Here, we investigate the effect of binding site conformation
on virtual screening by targeting the agonist/nanobody-bound
activated state of the β2AR. We prospectively screen the ZINC
library of 3.4 million “lead-like” and “fragment-like” molecules
against this target, experimentally testing 22 high-ranking
molecules for activity against the β2AR. For each docking hit,
we evaluated G protein and β-arrestin mediated signaling in
cells.15−19 To control for the role of library bias, in parallel we
undertook a ligand-based screen of the same ZINC library,
testing 30 molecules predicted by two-dimensional chemical
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similarity to resemble the co-crystallized ligand BI-167107 and
six additional β2AR agonists.
Finally, we investigated whether the active β2AR structure
can act as a modeling template to predict other active GPCR
structures, that is, whether the structural information encoded
in the active structure is transferrable. Previous work has
suggested that GPCR structures of suitably high sequence
identity in the inactive state can reliably template the modeling
of other GPCRs for predictive virtual screening.20 Determining
activated GPCR states will often be more challenging then
inactivate states,21 and the ability to use one active structure as
a model for others, as well as recapitulating the activated
function in the ligands, would have wide impact.
■ RESULTS AND DISCUSSION
We first carried out a retrospective docking of known β2AR
ligands to the active structure. At the time we undertook this
study, the agonist-bound structure of β2AR available was
stabilized in the active conformation by a potent agonist, BI-
167107, and by a G protein mimetic nanobody (PDB ID 3P0G,
referred to as the “active structure”). This structure is almost
identical in the binding site to a later active structure co-
crystallized with BI-167107 and the G protein itself (PDB ID
3SN6) that we did not use due to lower resolution in the
binding site. Using a set of 30 β2AR agonists and 30 β2AR
inverse-agonists,22 we tested the active structure’s ability to
recognize known β2AR ligands against a background of
property matched decoys23 and to preferentially score agonists
over inverse-agonists. We used the metric of adjusted LogAUC,
which measures the ranking of true positives (known ligands)
over false positives (decoy molecules) compared to what would
be expected at random (an adjusted LogAUC of 0 represents
the random ranking). This measure emphasizes early enrich-
ment of ligands, as the first 0.1% of the database is weighted
equally to the next 0.1−1% of the database, and to the next 1−
10% and 10−100% of the database.24,25 The active structure
enriched the 60 known β2AR ligands over computational
decoys, with an enrichment of 23.6% adjusted LogAUC. As well
as recognizing known ligands, the active structure also
distinguishes agonists from inverse-agonists, with adjusted
LogAUC of 35.4% for agonists and 10.6% for inverse-agonists
(Supplementary Figure S1). In the top 1% of the database, 20%
of agonists were found (6/30 docked agonists), while at 10% of
the database, 75% (22/30 agonists) were found. Using the
same set of agonists and inverse-agonists with the same decoys,
the inactive carazolol-bound β2AR crystal structure (PDB ID
2RH1) found no agonists in the top 1% of the database and
13% (4/30 agonists) in the top 10% of the database. For
comparison, the inactive β2AR structure enriched inverse-
agonists, with 6% (2/30 inverse-agonists) in the top 1% of the
database and 46% (14/30 inverse-agonists) in the top 10% of
the database (Supplementary Figure S1).
To ensure that docking enriched known agonists for the right
reasons, we confirmed that they not only scored well but also
were docked in reasonable poses. Residues Ser2035.42,
Ser2045.43, and Ser2075.46 in TM5 are proposed to be important
for interaction with agonists and activation in mutagenesis
studies,26,27 and the greatest structural change between active
and inactive β2AR is centered around those residues. We
evaluated the docked poses of known β2AR agonists by two
criteria: (1) the aminergic group should salt-bridge with the key
residue Asp1133.32, and (2) the polar head groups should
hydrogen bond with at least one of the three TM5 serine
residues (Figure 1A). The high retrospective enrichment of
known ligands, high ranking of agonists, and reasonable docked
poses encouraged us to move forward with a prospective virtual
screen.
For the prospective virtual screen, we used DOCK 3.6 to
virtually screen the 2.7M “lead-like” and 400K “fragment-like”
molecules of the ZINC database (July 2011).28,29 Essentially
this represents commercially available molecules with molecular
weights below 350, logP less than 3.5, and 7 or fewer rotatable
bonds. Molecules were screened to both the active and inactive
crystal structure. The ZINC subsets (lead or fragment-like)
were ranked separately, and only those that ranked at the top
0.2% to the active structure were considered. To select for
agonists, we only considered molecules with higher ranking in
the active structure than the inactive structure, as this would
reflect the structural bias we found in the active structure.
Molecules were filtered for a rank difference of at least 5000
between the active and inactive screen. An automatic filter was
applied to select for molecules that posed well, namely, having
(1) a positive charge, (2) an amine interaction to Asp1133.32,
and (3) a hydrogen bond interaction to Ser2035.42, Ser2045.43,
or Ser2075.46. Inverse-agonists in the inactive structure also
make the amine to Asp1133.32 interaction and hydrogen bond
to Ser2035.42, so we do not believe this filter unfairly biased the
results. Docking ranks reported here reflect the rankings prior
to filtering.
After visual inspection, 22 molecules were selected for
experimental testing from the top ∼0.2% of each subset: 17
lead-like molecules ranked in the top 5000 (out of 2.7M) and 5
Figure 1. Two partial β2AR agonists with new activating chemotypes in their docked poses. (A) The docked pose of isoproterenol, with a salt-bridge
between the amine group and key residue Asp1133.32 and hydrogen bonds to Ser2035.42, Ser2045.43, and Ser2075.46 in TM5. The co-crystal ligand BI-
167107 is shown in black sticks. Previously unreported (B) imidazole, compound 10, and (C) amino-purine, compound 14, polar head groups make
activating hydrogen bonds with TM5.
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Table 1. Hits Found in Virtual Screening of the Active β2AR Structure
aTanimoto coefficient (Tc) calculated for all known β2 adrenergic receptor ligands in the ChEMBL 15 database.
b“Fragment-like” screen. cBinding
assays performed with [125I]cyanopindolol. dNot determined.
Figure 2. Functional assays for β2AR agonists. Six compounds considerably increased cAMP formation and β-arrestin recruitment, consistent with
agonism (compounds 1, 4, 10, 12, 14, and 22 as indicated colors). (A) Dose−respone curves measuring G-protein activation through cAMP
formation using the GloSensor assay. (B) Known β2AR agonists used as controls in the GloSensor assay: isoproterenol (ISO, black), epinephrine
(Epi, green), hydroxybenzylisoproterenol (HBI, blue), and BI-167107 (BI, red). (C) Dose−response curves measuring β-arrestin recruitment using
the β2 V2R Tango assay. For compound 4, a connected line of each data point is presented instead of its dose−response curve since its fitting was
not converged. (D) The control β2AR agonists in the Tango assay as described for panel B. Each data point represents mean ± SE obtained from
three independent experiments done in duplicates. Dose−response curves for each compound were obtained using the nonlinear iterative curve-
fitting computer program Prism.
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fragment-like molecules ranked in the top 400 (out of 400K).
Molecules were selected for chemical diversity (Supplementary
Table S1) and, as is typical, for criteria missing from the DOCK
scoring function (detailed criteria may be found in ref 6 and are
described in the Supporting Information Methods). These
molecules were experimentally tested in HEK293 cells stably
transfected with the human β2AR, measuring Gs protein
activation through cAMP formation using the GloSensor
assay30 and β-arrestin recruitment using the Tango assay.31
The sensitivity of the Tango assay is improved by using a β2AR
mutant (β2/V2R) that has its carboxy-terminal tail replaced
with that of the vasopressin 2 receptor. This receptor has higher
affinity for binding to β-arrestins while retaining the ligand
binding properties of the native β2AR.31
Six compounds of the 22 tested (27%) considerably
increased cAMP formation, consistent with agonist activity,
and four out of these six compounds also significantly increased
β-arrestin recruitment (Table 1, Figure 2). The experiments
were repeated for all 22 compounds with the addition of either
2 nM isoproterenol for cAMP formation or 200 nM for β-
arrestin recruitment to test for antagonism; none of the
compounds significantly inhibited activation by isoproterenol
(data not shown). In summary, six hits were found, four full
agonists (compounds 1, 4, 12, 22) and two partial agonists
(compounds 10, 14). The two partial agonists are not predicted
to interact with both Ser2035.42 and Ser2075.46 in TM5, perhaps
leading to only partial agonism. Radioligand competition
binding assay was carried out to confirm binding of the six
hits to the β2AR using [125I]cyanopindolol with crude
membrane fractions containing the overexpressed β2AR
(Supplementary Figure S2). The binding affinity of agonists
is relatively weaker compared to their affinities in the functional
assays presumably due to the absence of G protein or β-
arrestin. Their engagement is essential for stabilizing a high
affinity state of the agonist binding conformation. In addition,
affinity measured by the different assays cannot be directly
compared, as differences in receptor reserve and amplification
must be taken into account.32 Second-messenger assays such as
the GloSensor assay have significant amplification, whereas the
Tango and direct binding assays do not.
An important advantage of structure-based virtual screening
is the ability to identify wholly new chemotypes. To measure
novelty, we assess chemical similarity to known ligands in
ChEMBL1533 using ECFP4 topological fingerprint and
Tanimoto coefficient (Tc).
34 The four full agonists predicted
contain the classical activating catecholamine moiety, support-
ing the notion that this is a privileged scaffold (Table 1).
Compound 12 was later found to be the known agonist
protokylol; however, this was not known to us at the time of
the screening. Likewise, compound 1 is also very similar to the
known agonist hydroxybenzylisoproterenol (HBI), with Tc of
0.74. Encouragingly, the two partial agonists (compound 10,
14) we predicted are novel, interacting with TM5 through
previously unknown chemical moieties: an imidazole and an
amino-purine (Figure 1B,C), with a Tc of 0.3 to any previously
known ligand (Table 1). A total of 4745 ligands are reported
for the human β2AR in ChEMBL15, reflecting the extensive
medicinal chemistry surrounding this target.
In addition to signaling through G proteins, GPCRs can also
stimulate β-arrestin mediated signaling, and certain ligands can
have different signaling efficacies for these distinct signaling
pathways.19,35 A “β-arrestin biased” ligand will have better
efficiency in recruitment of β-arrestin than in G protein
activation, when compared to an unbiased reference agonist
that signals with equal efficacy through G protein and β-arrestin
dependent pathways. Among the six agonists discovered,
compounds 1 and 12 both show some bias toward β-arrestin
recruitment (Table 1, Figure 2). Compared to the unbiased
agonist, isoproterenol,32 similar levels of G protein activation
were measured, with log(EC50) values in the GloSensor assay of
−9.5, −9.8, and −10.1 and Emax of 97%, 101% and 100% for
compound 1, compound 12, and isoproterenol, respectively.
On the other hand, these compounds showed higher levels of
β-arrestin recruitment when compared to isoproterenol, with
log(EC50) of −8.0, −8.3, and −8.1 and Emax of 159%, 141%,
and 100% in the Tango assay for compound 1, compound 12,
and isoproterenol, respectively. These β-arrestin recruitment
results were confirmed using another independent assay
(DiscoveRx PathHunter β-arrestin assay, Table 1, Figure 3A).
There have been several ways reported to calculate such a bias
of a ligand based on its potencies and efficacies in G protein
activation and β-arrestin recruitment assays.32 In order to
determine the degree of bias of the compounds 1 and 12, we
calculated their bias factors from the data sets in Figure 2 and
Figure 3A,B as well as binding affinity values (Supplementary
Figure S2) using the operational model.32 The bias factors of
the compounds 1 and 12 are around 1 when calculated from
both Tango and DiscoveRx β-arrestin against Glosensor cAMP
data sets (Figure 3C). These values indicate that they are
approximately 10 times more efficacious in β-arrestin recruit-
ment than in G protein-mediated cAMP production when
compared to isoproterenol, the unbiased reference. In fact, BI-
167107 itself shows stronger bias toward β-arrestin recruitment
with a bias factor around 1.5, indicating that it promotes β-
arrestin recruitment about 30 times more efficaciously than
cAMP production (Figure 3C). These data indicate that our
virtual screening with the active conformation of the β2AR/BI-
167107 co-crystal structure not only detected agonists but also
identified weakly biased agonists that have similar signaling bias
toward β-arrestin as BI-167107. Attempts to find β-arrestin
biased β2AR agonists have been almost intractable; to our
knowledge these are the first partially biased agonists to emerge
from virtual screening.
To deconvolute the influence of structure from library bias in
the docking, we screened the ZINC library using 2D chemical
similarity for additional β-arrestin biased agonists. We used the
Similarity Ensemble Approach (SEA), a statistical model that
ranks the significance of chemical similarity of a query molecule
to a set of ligands for a target.36 We used SEA to search the
ZINC database for molecules similar in 2D to a set of β2AR
agonists that are partially β-arrestin biased (unpublished data
and ref 32, as well as BI167107 (Supplementary Table S2)).
From the most significantly similar molecules, we visually
selected a diverse set of 30 compounds to test (compounds
SEA1−30, Supplementary Table S3). Of these, 11 were active
in the GloSensor assay (36%, Supplementary Figure S3). The
36% hit rate is consistent with the ability of ligand-based
screens to recall a known chemotype.37 Seven of the new
agonists resembled known adrenergic agonists (ECFP4 Tc >
0.35, Tc values for the 11 hits ranged from 0.31 to 0.70,
Supplementary Table S3). Perhaps less anticipated, and in
contrast to the β-arrestin biased molecules against which they
were selected, most of the predicted agonists did not induce
measurable β-arrestin recruitment (Supplementary Figure S3;
note that sensitivity in the Tango assay is approximately 2
orders of magnitude weaker than that in the Glosensor assay,
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making β-arrestin recruitment undetectable by Tango for a
majority of the hits that have substantially weak potencies in the
Glosensor cAMP assay). It was also surprising that the relatively
modest log(EC50) values were obtained in the Glosensor assay
for the ligand-based agonists, which ranged from −7.3 to −4.7.
These observations suggest that 2D chemical similarity alone
did not lead to the β-arrestin biased compounds found by
docking. We note that the partially β-arrestin biased agonists
used to construct the query set do not rank well to the active
structure, with none in the top 10% of the lead-like ZINC
database. This is likely because they have a larger number of
rotatable bonds, with 9.5 rotatable bonds on average for the 7
query-set partially biased molecules. Likewise, the compounds
selected on the basis of 2D similarity did not rank highly to the
active crystal structure when they were later docked to it, with
only one compound scoring in the top 10% of the database.
The ability to homology model active GPCR structures
would be a boon to the field, as agonists alone cannot fully
stabilize the active conformation and are consequently harder
to crystallize.21 To test whether the active β2AR structure could
template a closely related active GPCR structure, we modeled
and virtually screened an active dopamine D2 receptor (DRD2)
structure. Our homology modeling protocol, described
previously,6,20 produces many models and selects the best
model based on retrospective enrichment of docked known
binders from a background of property matched decoys.23 A
total of 500 models with identical backbone conformations and
different side chain orientations were generated using
MODELER v9.838 based on the active β2AR structure
(alignment shown in Supplementary Figure S4). No ligand is
present during the homology modeling. The final homology
model was chosen because it enriched known DRD2 ligands
and ranked agonists more highly then antagonists. The side
chain angle of the critical serine residues Ser1925.42, Ser1935.43,
or Ser1965.46 was enforced in all models to match that of the
active β2AR structure. To select a model we used retrospective
enrichment of known DRD2 ligands, and particularly agonists,
from a set of computationally derived decoy molecules. We
docked a chemically diverse set of 50 agonists and 50 inverse-
agonists as well as 6400 decoy molecules. The average LogAUC
for all generated models was 7.6% (±4.3%) for agonists and
6.7% (±2.9%) for inverse-agonists, with the selected model
having LogAUC of 16.9% and 10.5% for agonists and inverse-
agonists, respectively, far lower than the retrospective enrich-
ments found for the active β2AR (Supplementary Figure S1). A
previous virtual screen of a DRD3 homology modeled on the
inactive β2AR structure predicted ligands with hit rates,
novelty, and potency equaling that of the DRD3 crystal
structure,20 confirming the transferability of structural informa-
tion, at least with high sequence similarity, in the inactive state;
in unpublished studies, we have observed the same for the
DRD2 and serotonin 5HT2A receptors. A virtual screen of the
active DRD2 model would determine if the β2AR active
structure is likewise a good template. We screened the selected
active DRD2 model with the lead-like and fragment-like sets of
ZINC as described above, and 15 molecules were chosen from
the top 0.5% of each database (Supplementary Table S4; we
allowed a slightly larger slice of the database due to a prevalence
of high-internal-energy molecules that ranked highly and are
not penalized by the dock scoring function). These molecules
were further filtered corresponding to the criteria in the original
β2AR agonist screen: (1) a positive charge, (2) an amine
interaction to Asp1103.32, and (3) a hydrogen bond interaction
to Ser1925.42, Ser1935.43, or Ser1965.46. The reported ranks do
not reflect this pose filtering. Again, only molecules with a rank
difference of at least 5000 between the active and inactive
screen were considered; for the inactive screen we used the
DRD3 crystal structure, as DRD2 and DRD3 have 100%
sequence identity in the binding site. Molecules were tested as
described in GloSensor and Tango β-arrestin recruitment
assays to test for agonism and in the presence of 100 nM of
quinpirole to test for antagonism. Of the 15 molecules, three
Figure 3. An additional DiscoveRx PathHunter β-arrestin recruitment
assay and bias factors calculated using the operational model. (A)
Dose−response curves for the six β2AR agonists discovered in the
virtual screen. (B) Control compounds as described for Figure 2B.
Each data point represents mean ± SE, and dose−response curves for
each compound were obtained from three independent data sets. (C)
The bias factors of indicated compounds were calculated from the Tau
value analysis by the Operational Model32 using the data sets in Figure
2 and panels A and B of this figure, as well as the binding affinity values
obtained in Supplementary Figure S2. Each bar represents mean ± SE.
The statistical analysis was performed using one-way ANOVA with
Bonferroni’s multiple comparison post-test. *, P < 0.05; **, P < 0.01;
***, P < 0.001 compared to the reference value of isoproterenol
(ISO).
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were active in functional assays (20% hit rate, compounds 29,
33, 34; Table 2), of which two were agonists and one was an
inverse-agonist (GloSensor assay results shown in Figure 4).
We do not consider the three hits novel, with Tc values of
0.36−0.48 to known dopamine receptor ligands. Moreover, the
potency of the three hits was weak, suggesting that the active
β2AR structure was not a good template for the active DRD2,
despite high sequence homology and being a good template for
the inactive conformation, where hits bound with Ki of 200 nM
to 3 μM in binding affinity assays, of which several were
novel.20
Discussion. Two principal observations emerge from this
study: First, a prospective, large library screen against an
activated β2AR structure returned potent agonists, essentially
to the exclusion of inverse-agonists, with a high hit rate. This
study therefore provides the first complement to the previous
campaigns against inverse-agonist-bound structures, supporting
the functional fidelity of the docking hits to the conformation
of the GPCR target. Not only did we exclusively find agonists, a
handful also recapitulated the partial bias toward β-arrestin
signaling of the co-crystallized agonist BI-167107. The
structure-to-function link is strengthened by the results of the
2D ligand-based control screen, which was designed to predict
similarly arrestin biased ligands but produced none. In addition,
two previously unreported agonist chemotypes were found.
Second, a corollary of this functional fidelity is that, unlike the
inverse-agonist-bound structure, the agonist-bound state
provides an uncertain template for modeling the activated
state of other GPCRs. Although we did find agonists against the
D2 receptor, they were mixed with one antagonist, the hit rate
was lower, the compounds had lower affinities, and the agonism
was weaker.
In our screen of the activated β2AR structure, all hits
mirrored the agonist activity of the co-crystal ligand. This in
itself was unexpected in view of the subtle conformational
changes in the binding site upon activation. An inward bulge of
TM5, centered at Ser5.46, as well as rotation of the Ser5.42 and
Ser5.46 side chains, allows the active structure to discriminate
between docked agonists and antagonists. These activating
interactions are captured in the docked poses of the novel
partial agonists discovered, as well as the catecholamine hits.
The inactive structure does not allow for these favorable
electrostatic interactions, as the serines are pointed away from
the binding site, and for this reason agonists do not rank as
highly when docked to it.
Also remarkable was the observation that two of these hits
recapitulated the properties of the co-crystal ligand BI-167107
in terms of G protein and β-arrestin mediated signaling. These
two compounds have similar (but weaker) bias factors
compared to those of BI-167107 determined by the operational
model32 (Figure 3C). It is currently unknown whether the
crystallized, BI-167107-bound β2AR structure represents a
somewhat β-arrestin biased conformation. Compounds 1 and
12 discovered in our screen represent the first partially biased
Table 2. Hits Found in Virtual Screening of the Active DRD2 Model
aTanimoto coefficient (Tc) calculated for all known dopamine D2 receptor ligands in the ChEMBL 15 database.
bRank after filtering for a high-
internal energy motif not captured by the DOCK scoring function. cNot determined.
Figure 4. Functional assays for DRD2 agonists and inverse-agonists.
(A) Two compounds (29 and 33, green and blue squares, respectively)
activated Gi in GloSensor assays, consistent with partial agonism. QUI
is the known agonist quinpirole (black circle). (B) The GloSensor
assay was run in inverse-agonist mode with addition of 100 nM
quinpirole. One compound (38, red square) inhibited Gi activation.
HAL is the known inhibitor haloperidol (black diamond).
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compounds to be found by virtual screening. However, we
could not arrive at similarly β-arrestin biased compounds using
only 2D chemical similarity to the co-crystal ligand and other
agonists with comparable signaling profiles (Supplementary
Figure S3). The structure-based docking may be capturing
structural information encoded in the co-crystal structure;
however, as the conformation was crystallized in the presence
of a G protein mimetic nanobody, what if any biased structural
information was exploited by virtual screening remains opaque.
The active structure led to the prediction of two
unprecedented β2AR activating chemotypes, an imidazole and
an amino-purine (compounds 10 and 14, Table 1, Figure
1B,C). All of the catecholamines tested (4 of the 22
compounds tested) were found to be agonists (Table 1, Figure
2). Although these were predicted by docking, we do not
consider their identification remarkable in itself, as they could
have been predicted by any pharmaceutical chemist familiar
with β2AR agonists. In contrast, the discovery of two new
agonist chemotypes for a well studied GPCR such as β2AR is in
itself an interesting result and emphasizes the ability of virtual
screening to predict novel chemical scaffolds even in a crowded
field. Admittedly, these two scaffolds were the only ones that
were active of the 16 novel molecules, those with Tc ≤ 0.35 to
known β2AR ligands, that were tested. Unlike inverse agonists,
agonists must not only bind to the receptor but must also make
activating interactions with it, and there may be few
chemotypes that can do so in our current libraries.
More generally, we asked if the active β2AR structure could
act as a modeling template to predict other active GPCR
structures. The ability to model active structures for agonist
prediction would be particularly useful as active structures are
difficult to crystallize. While inactive structures of the
bioaminergic receptors have been solved in remarkably similar
conformations, it is unknown whether active conformations of
bioaminergic receptors are also alike. Virtually screening the
active DRD2 model predicted only two weak agonists, as well
as an inverse-agonist (Table 2, Figure 4); hit rates and
potencies were far lower when compared to the screen of the
active β2AR structure and as compared to a similar screen of an
inactive DRD3 model templated on the inactive β2AR
structure.20 These results indicate that despite 42% sequence
identity, structural information from the active β2AR was not
transferrable. The agonist state may be more particular to any
given GPCR−ligand pair, reducing the transference of
structures. Whether this observation is applicable to other
GPCRs remains to be determined and will become clear as
more active structures are determined.
Several cautions should be aired. First, we used domain
knowledge of the β2AR residues important for agonist
recognition to prioritize molecules, as is common practice in
the field. Since these interactions are also found in inverse-
agonists, they alone would not ensure us of agonists. Top
ranked molecules from the large-scale docking screen were
filtered on the basis of data implicating residues Ser5.42, Ser5.43,
and Ser5.46 in activation. Additionally, the measured β-arrestin
bias of compounds 1 and 12 remains modest, as is, in fact, that
of the co-crystal ligand BI-167107. The bias was, however,
confirmed independently in two separate assays, Tango and
DiscoverX. Finally, the low hit rate produced by the active
DRD2 model does not preclude other explanations: database
bias may still play a role, although dopamine agonists are well
represented in the pharmacopoeia. Dopamine agonists may
simply be harder to predict or to assay. DRD2 couples to the
inhibitory G protein Gi (rather than stimulatory Gs as β2AR
does), and accordingly, measurement of G protein signaling is
less straightforward. It may be that the lack of transferability
from the active β2AR structure to active DRD2 is particular to
this case or to our modeling and docking protocols.
Conclusions. A large library virtual screen of the activated
BI-167107/β2AR co-crystal structure predicted exclusively
agonists, just as previous virtual screens of inactive GPCR
structures predicted exclusively inverse-agonists. The remark-
able functional fidelity of the docking hits to the form of the
receptor has important implications for drug design: small
molecule GPCR ligands induce a variety of signaling behaviors,
most likely through subtly different receptor conformations. As
co-crystal GPCR structures with these ligands emerge, virtual
screening might be used to predict new ligands with similar
signaling properties. However, structural information from the
activated β2AR structure was not transferrable to the closely
related active dopamine D2 receptor structure, suggesting that
the agonist state is more particular to a given GPCR-ligand pair.
■ METHODS
Homology Modeling and Docking. We used DOCK 3.625 to
screen the ZINC database as described (see Results). Complimentarity
of each ligand pose is scored as the sum of the receptor−ligand
electrostatic and van der Waals interaction energy and corrected for
ligand desolvation. Partial charges from the united-atom AMBER force
field were used for all receptor atoms except for Ser5.42, Ser5.43, and
Ser5.46, for which the dipole moment was increased as previously
described3 to boost electrostatic scores for poses in polar contact with
these important residues. The hit list was automatically filtered to
remove a previously known high-internal-energy motif that results in
unreasonably favorable docking scores and for favorable activating
interactions with the receptor, as described (the rankings reported do
not reflect this further filtering). MODELER v9.838 was used for
DRD2 homology model generation, based on PDB ID 3P0G as the
active template.
Materials. Compounds were obtained from commercial vendors,
as well as from the Developmental Therapeutics Program at the
National Cancer Institute. All compounds were sourced at 95% or
greater purity. All active compounds were further tested for purity by
LC−MS, at UCSF, and were found to be pure as judged by peak
height and identity. Bright-Glo and Glosensor reagents were obtained
from Promega (Madison, WI). The Tango construct for the β2 V2R
and the parental Tango cell line expressing β-arrestin2-TEV and
luciferase reporter protein were provided by Gilad Barnea and Richard
Axel. The stable cell line and the reagents for the β2AR DiscoveRx
PathHunter β-arrestin assay were obtained from DiscoveRx (Fremont,
CA).
β2AR Functional and Binding Affinity Assays. G protein
activation and β-arrestin recruitment to receptor was measured in the
GloSensor cAMP accumulation assay and the Tango assay,
respectively, as previously described.32 To ensure that the results
obtained using the Tango assay were not an artifact of overnight
incubation, we also used the PathHunter β-arrestin assay from
DiscoverRx, which has shorter incubation time.32 All functional assays
were done using stably transfected cell lines. Radioligand binding
assays were performed with crude membrane fractions from β2AR
stably overexpressing HEK-293 cells, using 60 pM [I125]-cyanopindo-
lol as a tracer.39
DRD2 Functional and Binding Affinity Assays. GloSensor,
Tango, and binding affinity assays were carried out at the National
Institute of Mental Health Psychoactive Drug Screening Program as
previously described.40,41
Data Analysis. Calculation of EC50, binding affinitiy (Ki), and Tau
values, as well as dose−response curves, were obtained using the
nonlinear iterative curve-fitting computer program Prism (GraphPad
Software Inc., San Diego, CA).
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